Truist Securities Maintains Buy on Eli Lilly, Raises Price Target to $1033
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has maintained its Buy rating on Eli Lilly and raised the price target from $1000 to $1033, indicating confidence in the company's future performance.
October 10, 2024 | 1:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities has reaffirmed its Buy rating on Eli Lilly and increased the price target from $1000 to $1033, suggesting a positive outlook for the company's stock.
The increase in price target from $1000 to $1033 by Truist Securities indicates a positive sentiment towards Eli Lilly's future performance. This is likely to boost investor confidence and potentially lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100